Effects of 4-Aminopyridine on cloned hERG channels expressed in mammalian cells

Archives of Drug Information

Volumn 2, Issue 3, 2009, Pages 51-57

  Renganathan, Muthukrishnan ^a   Sidach, Serguei ^b   Blight, Andrew R ^c  

^a Millipore Corporation   (United States)

^b TARGACEPT INC   (United States)

^c ACORDA THERAPEUTICS INC   (United States)

Author keywords

4 Aminopyridine (Fampridine); Cardiac Toxicity; Human Embryonic Kidney 293 (HEK293) Cells; Humaneth er go go Related Gene (hERG); IKr (Delayed Rectifier Potassium Current); IC50 (Concentration Resulting in 50 Inhibition); Multiple Sclerosis; Potassium Channel Blocker; QT Interval Prolongation; Torsade de Pointes (TdP)

Indexed keywords

4 AMINOPYRIDINE; DELAYED RECTIFIER POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; TERFENADINE;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; EMBRYO; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; MAMMAL CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; STABLE TRANSFECTION; STEADY STATE; TORSADE DES POINTES; VOLTAGE CLAMP;

EID: 72249100135     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2009.00021.x     Document Type: Article

References (24)

1. Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41.
2. Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, et al. Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68.
3. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994;51:292-6.
4. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21.
5. Coetzee WA, Amarillo Y, Chiu J, Chow A, Lau D, McCormack T, et al. Molecular diversity of K+ channels. Ann N Y Acad Sci 1999;868:233-85.
6. Gold MS, Shuster MJ, Levine JD. Characterization of six voltage-gated K+ currents in adult rat sensory neurons. J Neurophysiol 1996;75:2629-46.
7. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004;15:475-95.
8. Sanguinetti MC, Keating MT. Role of delayed rectifier potassium channels in cardiac repolarisation and arrhythmias. News Physiol Sci 1997;12:152-7.
9. US Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2005. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm129335.htm (accessed June 12, 2009).
10. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
11. US Food and Drug Administration [Internet]. ICH S7B Guideline. Step 2 Revision. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. 2004. Available at: http://www.fda.gov/cder/guidance/ 5533dft.htm (accessed November 20, 2008).
12. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
13. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1996;269:92-5. Erratum in: M.C. Trudeau, J.W. Warmke, B. Ganetzky, G.A. Robertson, HERG sequence correction, Science 1996;272:087.
14. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999;10:272-82.
15. Witchel HJ. The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets 2007;11:321-36.
16. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006;316:1098-106.
17. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74:230-41.
18. Joshi A, Dimino T, Vohra Y, Cui C, Yan GX. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: The role of experimental models. J Electrocardiol 2004;37(suppl):7-14.
19. Ridley JM, Milnes JT, Zhang YH, Witchel HJ, Hancox JC. Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine. J Physiol 2003;549(Pt 3):667-72.
20. Hayes KC, Katz MA, Devane JG, Hsieh JT, Wolfe DL, Potter PJ, et al. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;43:379-85.
21. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005;26:590-7.
22. Smeets JW, Kunst MW. Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 1995;139:2667-9.
23. Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004;85:29-34.
24. Isoda WC, Segal JL. Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury. Pharmacotherapy 2003;23:133-6.